Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

Carfilzomib, the next generation of proteasome inhibitor, may increase osteoblast-related markers in patients with multiple myeloma, but the molecular mechanism of its effect on mesenchymal stem cell differentiation to osteoblasts remains unknown. Herein, we demonstrated that carfilzomib significant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hu, Bo, Chen, Yu, Usmani, Saad Z., Ye, Shiqiao, Qiang, Wei, Papanikolaou, Xenofon, Heuck, Christoph J., Yaccoby, Shmuel, Williams, Bart O., Van Rhee, Frits, Barlogie, Bart, Epstein, Joshua, Qiang, Ya-Wei
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2013
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3774816/
https://ncbi.nlm.nih.gov/pubmed/24066119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0074191
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi